Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Orbactiv

EU flag

EMA backs 15 new medicines for use in EU

Includes new treatments from Gilead, Lilly, Boehringer, AstraZeneca and Janssen

- PMLiVE

Cubist launches Zurich base

US antibiotic company expands into Europe

- PMLiVE

Drug regulators collaborate to tackle Ebola outbreak

EMA and FDA team up with global partners to accelerate access to medicines

- PMLiVE

Amgen submits melanoma and cholesterol drugs to EMA

Regulator will assess talimogene laherparepvec and evolocumab

- PMLiVE

EMA names head of comms team

Marie-Agnes Heine joins regulator from World Health Organization

- PMLiVE

Rapid review for Pfizer’s superbug vaccine

FDA to expedite assessment of Clostridium difficile inoculation

- PMLiVE

EMA accepts Cubist antibiotic for review

Follows FDA priority review for ceftolozane/ tazobactam

- PMLiVE

FDA approves antibacterial skin drug Orbactiv

US regulator authorises Medicines Company's treatment for ABSSSI

- PMLiVE

Two blood cancer drugs among CHMP recommendations

Five new drugs, including Janssen’s Imbruvica and Gilead’s Zydelig, backed for use in Europe

UK flag

Antimicrobial resistance priority for new UK science minister

Greg Clark announces collaboration led by Medical Research Council

EU flag

EMA transparency policy delayed over ‘wording’

Regulation on access to trial data postponed until October

UK flag

UK healthcare professionals urged to say ‘no’ to antibiotics

Royal Colleges issues joint statement to members warning of antimicrobial resistance

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links